The downgrade from Buy to Neutral by a major analyst, along with a significant reduction in the price target, is likely to negatively impact investor sentiment and the stock price of RAPT Therapeutics in the short term. Such a drastic change signals a substantial shift in the expected performance of the company, potentially leading to a decrease in stock price as investors adjust their expectations.